Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial

Autor:	Michel Delforge, Paula Rodríguez Otero, Nina Shah, Olga Moshkovich, Julia Braverman, Devender S. Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B. Campbell, Nikhil C. Munshi
Rok vydání:	2023
Předmět:	Cancer Research Oncology Hematology
Zdroj:	Leukemia Research. 129:107074
ISSN:	0145-2126
DOI:	10.1016/j.leukres.2023.107074
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8117febce698bb52c954ac319e3c1c70 https://doi.org/10.1016/j.leukres.2023.107074 Zobrazit plný text záznamu Full Text from ScienceDirect